What is the 13F Pro Quality Score for COSM?

13F Pro ranks Cosmos Health Inc. (COSM) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View COSM's current score at https://13fpro.ai/research/COSM (free sign-up required for the full ranking).

Where does 13F Pro source COSM data?

All Cosmos Health Inc. fundamentals and ownership data come directly from SEC EDGAR. Cosmos Health Inc. files with the SEC under CIK 1474167. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is COSM in?

Cosmos Health Inc. (COSM) is classified in the Consumer Staples sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/consumer-staples.

How often is COSM research updated on 13F Pro?

COSM's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cosmos Health Inc.(COSM)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Consumer Staples →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1474167 COSM stock profile & AI dashboard →

13F Pro Quality Score

28.9/100

Rank #2,424 of 2,879 stocks

View Consumer Staples peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

66.2/100

Profitability

20.0/100

Balance Sheet

12.5/100

Earnings Quality

30.0/100

Free Cash Flow

20.7/100

Institutional Flow

32.1/100

Revenue Scale

13.3/100

Dilution Risk

31.1/100

COSM Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cosmos Health Inc. (COSM), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores COSM at 28.9/100 on a 32-signal composite quality model, placing it at rank #2,424 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include balance sheet strength (12.5) and revenue scale (13.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cosmos Health Inc. reports quarterly revenue of $17.9M, net income of $-2.8M, free cash flow of $-1.1M. Top institutional holders of COSM by reported 13-F value include RENAISSANCE TECHNOLOGIES, GEODE CAPITAL MANAGEMENT,, CITADEL ADVISORS, based on the most recent SEC filings. COSM trades on the Nasdaq exchange and files with the SEC under CIK 1474167. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cosmos Health Inc. directly from SEC EDGAR. Cosmos Health Inc.'s 13F Pro composite quality score has ranged between 17 and 29 since 2023, currently 28.9 — an improving long-term trajectory across 20 quarterly and live scoring snapshots.

Revenue

Q1 2026

$17.9M

Net Income

Q1 2026

$-2.8M

Free Cash Flow

Q1 2026

$-1.1M

D/E Ratio

Q1 2026

0.17

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+2.0% YoY

$54.4MFY 2024

FY21 $56.2MFY22 $50.3MFY23 $53.4MFY24 $54.4M

Net Income

+12.7% YoY

$-16.2MFY 2024

FY21 $-8.0MFY22 $-13.8MFY23 $-18.5MFY24 $-16.2M

Operating Income

+28.8% YoY

$-15.5MFY 2024

FY21 $-4.5MFY22 $-7.5MFY23 $-21.8MFY24 $-15.5M

EPS (Diluted)

+45.6% YoY

$-1.17FY 2024

FY21 $-0.95FY22 $-33.16FY23 $-2.15FY24 $-1.17

Total Assets

-17.7% YoY

$54.3MFY 2024

FY21 $49.4MFY22 $68.0MFY23 $66.0MFY24 $54.3M

Total Debt

-36.9% YoY

$4.1MFY 2024

FY21 $17.9MFY22 $5.0MFY23 $6.5MFY24 $4.1M

Op. Cash Flow

+50.6% YoY

$-7.7MFY 2024

FY21 $-7.1MFY22 $-14.9MFY23 $-15.6MFY24 $-7.7M

Metric	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2016
Revenue	$54.4M +2.0%	$53.4M +6.0%	$50.3M -10.5%	$56.2M +1.5%	$55.4M +720.2%	$6.8M
Net Income	$-16.2M +12.7%	$-18.5M -34.1%	$-13.8M -73.7%	$-8.0M -1070.0%	$820.8K +236.6%	$-601.0K
Operating Income	$-15.5M +28.8%	$-21.8M -192.1%	$-7.5M -64.9%	$-4.5M -267.0%	$2.7M +1440.3%	$-202.5K
EPS (Diluted)	$-1.17 +45.6%	$-2.15 +93.5%	$-33.16 -3390.5%	$-0.95 -1683.3%	$0.06 -100.0%	$80741.00
Total Assets	$54.3M -17.7%	$66.0M -3.0%	$68.0M +37.6%	$49.4M +12.7%	$43.8M +1305.9%	$3.1M
Total Debt	$4.1M -36.9%	$6.5M +29.8%	$5.0M -72.0%	$17.9M +66.2%	$10.8M	—
Operating Cash Flow	$-7.7M +50.6%	$-15.6M -5.1%	$-14.9M -109.5%	$-7.1M +38.3%	$-11.5M -441.0%	$-2.1M

AI Insight: COSM Financial Trends

Revenue grew 38% from Q2 2024 to Q1 2026, but persistent operating losses and deteriorating Q4 2025 cash burn signal operational struggles despite top-line expansion.

• Revenue increased from $13M (Q2 2024) to $18M (Q1 2026), a 38% gain over nine quarters.

• Total debt declined from $8M (Q2 2024) to $4M (Q1 2026), improving leverage profile.

• Operating income remained negative across all periods; Q4 2025 saw -$11M operating loss, the worst quarter recorded.

⚠ Q4 2025 operating cash flow collapsed to -$5M, sharply worse than prior quarters; only partially recovered to -$1M in Q1 2026.

⚠ Net losses persist despite revenue growth; Q4 2025 loss of -$10M suggests scale-up costs outpacing sales gains.

AI Insight: COSM Ratio Trends

Cosmos Health remains deeply unprofitable with deteriorating margins and erratic quarterly swings; no clear path to profitability visible.

• Operating margin contracted to -12.2% in Q1 2026 from -6.1% in Q1 2025, reversing prior-year improvement.

• TTM operating margin stands at -26.0%, net profit margin at -30.4%; company lost money on operations across trailing twelve months.

• Leverage spiked to 0.42x D/E in Q4 2025 before retreating to 0.20x in Q1 2026; elevated volatility suggests structural weakness.

⚠ Q4 seasonal cliff persists: OpMargin fell to -57.9% in Q4 2025, mirroring -63.0% in Q4 2024; investigate underlying cause.

⚠ Net profit margin swung wildly from -6.0% (Q1 2025) to -31.3% (Q3 2025); earnings stability absent, forecasting difficult.

⚠ ROA has remained deeply negative (range: -5.7% to -70.3%); no quarter shows asset productivity improvement.

Get alerted when COSM's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cosmos Health Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of COSM

RENAISSANCE TECHNOLOGIES LLC
$123.9K390,500 sh
GEODE CAPITAL MANAGEMENT, LLC
$100.9K318,111 sh
CITADEL ADVISORS LLC
$94.0K296,300 sh
BlackRock, Inc.
$84.9K267,797 sh
VANGUARD CAPITAL MANAGEMENT LLC
$44.4K140,007 sh
VANGUARD FIDUCIARY TRUST CO
$30.3K95,735 sh
STATE STREET CORP
$14.4K45,243 sh
XTX Topco Ltd
$12.8K40,477 sh
CITADEL ADVISORS LLC
$12.8K40,306 sh
NORTHERN TRUST CORP
$6.5K20,554 sh

Fund	Value	Shares
RENAISSANCE TECHNOLOGIES LLC	$123.9K	390,500
GEODE CAPITAL MANAGEMENT, LLC	$100.9K	318,111
CITADEL ADVISORS LLC	$94.0K	296,300
BlackRock, Inc.	$84.9K	267,797
VANGUARD CAPITAL MANAGEMENT LLC	$44.4K	140,007
VANGUARD FIDUCIARY TRUST CO	$30.3K	95,735
STATE STREET CORP	$14.4K	45,243
XTX Topco Ltd	$12.8K	40,477
CITADEL ADVISORS LLC	$12.8K	40,306
NORTHERN TRUST CORP	$6.5K	20,554

More Consumer Staples Companies

View all Consumer Staples →

ABEV

AMBEV S.A.

ABVE

Above Food Ingredients Inc.

ACI

Albertsons Companies, Inc.

ADM

Archer-Daniels-Midland Co

AFRI

Forafric Global PLC

AGCC

Agencia Comercial Spirits Ltd.

AGRO

Adecoagro S.A.

AGRZ

Agroz Inc.

Put COSM on your watchlist

Track score changes the day Cosmos Health Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is COSM a good stock to buy?

13F Pro's AI-powered analysis of Cosmos Health Inc. (COSM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COSM are available on the COSM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own COSM?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COSM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cosmos Health Inc.'s investment landscape.